Avistone Pharmaceuticals
Brand
Avistone operates two wholly-owned subsidiaries:

Beijing Purun'ao Biotechnology Co.,Ltd. incorporated in 2012, and
Avistone Pharmaceuticals Biotechnology Co.,Ltd. incorporated in 2018

2012
Inception of Beijing Purun'ao Biotechnology Co.,Ltd.
2018
Inception of Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
Search More
Search More
About the Team
Team
Sharing the same dream and targets, a group of talented individuals came together. They helped and encouraged each other, overcoming all obstacles and challenges to forge a bright future for others.
Search More
Search More
  • Shi Hepeng
    Founder, Chairman and CEO of Avistone
  • Zhang Peilong
    Chief Technology Officer, Avistone
  • David Chung
    Chief Business Officer, Avistone
  • Kevin Schaab, Ph.D.
    VP, Non-Clinical Development & CMC
Science & Innovation
products

Clinical study of MET exon 14 mutation and primary

MET amplification in non-small cell lung cancer:

2021-12-09
Avistone Completes $200 Million-plus Fundraising, with Vivo Capital as the Lead Investor
On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") announced the closure of Series A funding, raising over $200 million.
2022-09-28
Acceptance of Avistone's application for launch of MET inhibitor Vebreltinib enteric capsule (PLB-1001) in China
Avistone recently announced the application by its subsidiary Purun'ao Biotechnology for the launch of its Vebreltinib enteric capsule. The application has been accepted on September 24 by the National Medical Products Administration for priority review. The proposed application of Vebreltinib is for the treatment of partial late-stage or metastatic NSCLC patient with Mesenchymal-epithelial transition factor (MET) Exon 14 skipping.
2022-09-15
Here comes the ranking list! Unveiling the Top 10 finalists in biomedical field for 2022 Zhongguancun International Frontier Technology Innovation Competition
On September 15, 2022, the finals for biomedical section in the 2022 Zhongguancun International Frontier Technology Innovation Competition was held in Zhongguancun Lif Sciences Park in Beijing's Changping District. Ten technology companies emerged from the rank and file and were named Top 10 finalists.
2022-03-15
Bain Headline | Bain Capital Invests in Innovative Drug Company Avistone Pharmaceuticals to Help It Build Cancer Precision Treatment Platform
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") recently announced closure of Series A funding, raising over $200 million.